secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sonnet BioTherapeutics Holdings, Inc. (—)
CIK:        0001106838
Form:       8-K
Filed at:   2025-07-14T23:59:59+00:00
Accession:  0001641172-25-018877
Event type: m_and_a
Sentiment:  negative
Materiality: 0.90
Item codes: 1.01, 3.02, 5.02, 5.03, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sonnet BioTherapeutics to merge with Hyperliquid-backed Rorschach; existing holders to own ~1.2% of Pubco
--------------------------------------------------------------------------------

- Sonnet stockholders receive 1 Pubco share + 1 CVR per share; Rorschach equityholders contribute ≥$200M HYPE tokens.
- Pubco to hold ~$583M in HYPE tokens and ≥$305M cash at close; $5.5M Initial PIPE plus $2M bridge conversion.
- Post-close, Rorschach/Subscribers own ~98.8% of Pubco; existing Sonnet holders ~1.2% (including PIPE investors).
- Closing expected H2 2025; subject to SEC registration, Nasdaq listing, and Sonnet stockholder approval.
- Chardan Capital Markets receives 7% of gross Closing PIPE proceeds; $2.5M termination fee if Sonnet board changes recommendation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1106838/000164117225018877/0001641172-25-018877-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1106838/000164117225018877/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-018877

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer